China Plasma Protein Therapeutics Market

China Plasma Protein Therapeutics Market Outlook 2031

• The industry was valued at US$ 4.3 Bn in 2021
• It is projected to grow at a CAGR of 5.7% from 2022 to 2031 and reach more than US$ 7.7 Bn by the end of 2031

Analysts’ Viewpoint on Market Scenario

The China plasma protein therapeutics market size is expected to grow at a significant pace in the next few years due to increase in the prevalence of chronic diseases. Plasma protein therapies are used for the treatment and management of various autoimmune disorders.

Rise in healthcare expenditure is anticipated to augment market progress during the forecast period. The Government of China is focused on improving the diagnosis and treatment of rare diseases. Surge in demand for gene therapy is likely to offer lucrative growth opportunities for vendors in the industry. Vendors are engaged in the approval and launch of new products to increase their China plasma protein therapeutics market share.

Market Introduction

Plasma protein therapeutics are proteins derived from human plasma. They are employed for the treatment of various medical conditions. Plasma protein therapeutics can be used for the treatment of blood disorders such as congenital fibrinogen deficiency, hemophilia A, Von Willebrand disease, and Disseminated Intravascular Coagulation (DIC). These disorders are caused by a deficiency or dysfunction of proteins involved in the blood clotting process. Plasma protein therapies help restore normal levels of these proteins in the body.

Plasma protein therapeutics can be utilized for the treatment of immune disorders such as primary immunodeficiency, autoimmune diseases, and certain infectious diseases. These disorders are caused by malfunctions in the immune system. Plasma protein therapies, such as Intravenous Immunoglobulin (IVIg) and anti-D immunoglobulin, can help boost the immune system.

Rise in Prevalence of Chronic Diseases Fueling China Plasma Protein Therapeutics Industry Statistics

Plasma protein therapeutics are used for the treatment of various chronic diseases such as cancer, cardiovascular diseases, and autoimmune diseases. Several factors contribute to the rise in cases of chronic diseases in China. Rapid industrialization has led to significant changes in people's lifestyles.

Rise in usage of motorized transportation and increase in the consumption of processed and high-calorie food products boost the risk of lifestyle disorders among the populace. Thus, surge in the incidence of chronic diseases is projected to contribute to China plasma protein therapeutics market growth in the next few years.

China is witnessing a gradual increase in the geriatric population, environmental pollution, and genetic predisposition. The proportion of people over the age of 65 years is expected to reach 20% of the overall population by 2035. This, in turn, is likely to boost the China plasma protein therapeutics market development in the near future.

Increase in Healthcare Expenditure

Public awareness regarding plasma protein therapies is increasing due to high prevalence of various chronic diseases. Plasma protein therapies increase life expectancy and the enhance quality of life. These therapies also reduce life-threatening complications in people suffering from plasma protein deficiencies.

Plasma protein therapeutics are expensive. This could lead to market limitations. However, surge in healthcare expenditure is estimated to drive the China plasma protein therapeutics market expansion in the next few years. The Government of China has invested significantly in the healthcare sector in the past few years. According to the World Bank, healthcare expenditure in China as a percentage of GDP has increased from around 4% in 2000 to nearly 9% in 2020.

Growth in Adoption of Immunoglobulins

According to the latest China plasma protein therapeutics market analysis, the immunoglobulins product type segment accounted for largest share in 2021. Growth in the incidence of immune-mediated diseases, such as autoimmune disorders, allergies, and immune deficiency disorders, is augmenting demand for immunoglobulin protein therapeutics.

R&D in protein engineering and manufacturing technologies is expected to offer more effective and safer immunoglobulin protein therapeutics. Presence of favorable reimbursement policies for immunoglobulin protein therapeutics also positively impacts segment growth.

Increase in Cases of Autoimmune Disorders

As per the latest China plasma protein therapeutics market insights, the immunology therapeutic area segment dominated the industry in 2021. Increase in the incidence of immune disorders is boosting the segment. Rheumatoid arthritis, systemic lupus erythematosus, Inflammatory Bowel Disease (IBD), and Multiple Sclerosis (MS) are some of the most common autoimmune disorders. Psoriatic, rheumatoid arthritis, and ankylosing spondylitis are the diseases with the highest number of cases in China.

Analysis of Key Players

The China plasma protein therapeutics market research report concludes with the company profiles section that includes key information such as product portfolio, recent developments, financial overview, company overview, strategies, and segments. Most companies focus on strategies such as new product launches, mergers & acquisitions, partnerships, and collaborations to compete in the marketplace.

Biognosys AG, Biotest AG, Taibang Biological Group, CSL Behring (CSL), Grifols, S.A., Kedrion S.p.A., Octapharma AG, Takeda Pharmaceutical Company Limited, and Shanghai RAAS are key entities operating in the China plasma protein therapeutics market. Several international pharmaceutical companies have established production facilities in China, which has led to surge in the domestic production of plasma protein therapeutics. This trend is expected to continue as the Government of China continues to implement policies to encourage the expansion of the domestic pharmaceutical industry.

Key Developments in China Plasma Protein Therapeutics Market

• In September 2022, Grifols signed a long-term agreement with Canadian Blood Services, Canada’s national blood authority, to increase the country’s self-sufficiency in immunoglobulin (Ig) medicines. Under the agreement, Grifols is expected to provide around 2.4 million grams of Ig annually.
• In March 2021, Biognosys announced its R&D roadmap for plasma proteomics as an unbiased, true discovery offering for large-scale applications

China Plasma Protein Therapeutics Market Snapshot